<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>9(6)</volume><submitter>Liu J</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Extracellular matrix proliferation is an issue which leads to lung tissue damage in diabetes mellitus. Glucagon-like peptide-1 (GLP-1) analogues can improve the proliferation of extracellular matrix in diabetic pulmonary disease. In this study, we investigated the effect of GLP-1 on pulmonary fibrosis through the AMPK/microRNA-27a (miR-27a) pathway.&lt;h4>Methods&lt;/h4>Human embryonic lung fibroblast (MRC-5) cells were cultured with a high-glucose medium, and were treated with miR-27a inhibitor, GLP-1 analogues, and AMPK inhibitor. Cell Counting Kit-8 (CCK-8) detected the proliferation of MRC-5 cells. The fibrosis-related genes were analyzed, including Col-IV, fibronectin, NF-κB p65, α-SMA, and TGF-β1. Bioinformatics and dual-luciferase reporter assays were used to identify the targets for miR-27a.&lt;h4>Results&lt;/h4>Compared with the control group, the expression of miR-27a in the hyperglycemic group was significantly up-regulated (P&lt;0.01) and the expression of peroxisome proliferator-activated receptor γ (PPARγ) significantly down-regulated (P&lt;0.01). The expression of Col-IV, fibronectin, NF-κB p65, α-SMA and TGF-β1 increased significantly (P&lt;0.01). The expression level of apoptosis factor caspase-3 decreased significantly (P&lt;0.01). MiR-27a inhibitor could reverse the expression of these proteins. The effect of GLP-1 on miR-27a was time- and concentration-dependent. After pretreating MRC-5 cells via GLP-1, with or without compound C (AMPK inhibitor), the expression of miR-27a in the GLP-1 treated group was significantly lower than that in Vehicle group. The expression of miR-27a was increased after inhibition of the AMPK pathway. A predictive TargetScan algorithm showed that the PPARγ gene was a potential target of miR-27a. MiR-27a was also shown to target 3'-UTR of PPARγ.&lt;h4>Conclusions&lt;/h4>MiR-27a plays an important regulatory role in diabetic pulmonary fibrosis. GLP-1 could down-regulate the expression level of miR-27a by activating AMPK. Furthermore, the target gene PPARγ was up-regulated, consequently improving extracellular matrix proliferation in MRC-5 cells.</pubmed_abstract><journal>Annals of translational medicine</journal><pagination>492</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8039657</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Glucagon-like peptide-1 (GLP-1) improved diabetic lung fibrosis via AMPK and microRNA-27a (miR-27a).</pubmed_title><pmcid>PMC8039657</pmcid><pubmed_authors>Li X</pubmed_authors><pubmed_authors>Liu J</pubmed_authors><pubmed_authors>Zheng X</pubmed_authors><pubmed_authors>Zhang X</pubmed_authors><pubmed_authors>Lu S</pubmed_authors><pubmed_authors>Zhao W</pubmed_authors></additional><is_claimable>false</is_claimable><name>Glucagon-like peptide-1 (GLP-1) improved diabetic lung fibrosis via AMPK and microRNA-27a (miR-27a).</name><description>&lt;h4>Background&lt;/h4>Extracellular matrix proliferation is an issue which leads to lung tissue damage in diabetes mellitus. Glucagon-like peptide-1 (GLP-1) analogues can improve the proliferation of extracellular matrix in diabetic pulmonary disease. In this study, we investigated the effect of GLP-1 on pulmonary fibrosis through the AMPK/microRNA-27a (miR-27a) pathway.&lt;h4>Methods&lt;/h4>Human embryonic lung fibroblast (MRC-5) cells were cultured with a high-glucose medium, and were treated with miR-27a inhibitor, GLP-1 analogues, and AMPK inhibitor. Cell Counting Kit-8 (CCK-8) detected the proliferation of MRC-5 cells. The fibrosis-related genes were analyzed, including Col-IV, fibronectin, NF-κB p65, α-SMA, and TGF-β1. Bioinformatics and dual-luciferase reporter assays were used to identify the targets for miR-27a.&lt;h4>Results&lt;/h4>Compared with the control group, the expression of miR-27a in the hyperglycemic group was significantly up-regulated (P&lt;0.01) and the expression of peroxisome proliferator-activated receptor γ (PPARγ) significantly down-regulated (P&lt;0.01). The expression of Col-IV, fibronectin, NF-κB p65, α-SMA and TGF-β1 increased significantly (P&lt;0.01). The expression level of apoptosis factor caspase-3 decreased significantly (P&lt;0.01). MiR-27a inhibitor could reverse the expression of these proteins. The effect of GLP-1 on miR-27a was time- and concentration-dependent. After pretreating MRC-5 cells via GLP-1, with or without compound C (AMPK inhibitor), the expression of miR-27a in the GLP-1 treated group was significantly lower than that in Vehicle group. The expression of miR-27a was increased after inhibition of the AMPK pathway. A predictive TargetScan algorithm showed that the PPARγ gene was a potential target of miR-27a. MiR-27a was also shown to target 3'-UTR of PPARγ.&lt;h4>Conclusions&lt;/h4>MiR-27a plays an important regulatory role in diabetic pulmonary fibrosis. GLP-1 could down-regulate the expression level of miR-27a by activating AMPK. Furthermore, the target gene PPARγ was up-regulated, consequently improving extracellular matrix proliferation in MRC-5 cells.</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Mar</publication><modification>2025-04-04T21:24:44.002Z</modification><creation>2025-04-04T21:24:44.002Z</creation></dates><accession>S-EPMC8039657</accession><cross_references><pubmed>33850889</pubmed><doi>10.21037/atm-21-869</doi></cross_references></HashMap>